Office of Research & Development |
![]() ![]() |
Project Number: | I01BX004751-01 |
Title: | Regulation of Targeted Therapeutic Response by the Immune Microenvironment in HNSCC |
Principal Investigator: | Lynn Heasley |
Location: | Denver, CO |
Congressional District Code: | 6 |
Research Service: | Biomedical Laboratory R&D |
Project Period: | July 2019 - June 2023 |
FY 2021 Funding Amount: | $250,322 |
Total Award Amount (all years): |
$1,146,931 |
Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Despite optimized therapeutic regimens, the 5-year survival rate for head and neck squamous cell carcinoma (HNSCC) remains around 50%. EGFR is a key component of a receptor tyrosine kinase (RTK) network that functions as a non-mutated “driver” in HNSCC cell lines and is the target for the FDA-approved agent, cetuximab. Individually, HNSCC patients exhibit wide-ranging extent of response to cetuximab as well as ERBB family- targeted tyrosine kinase inhibitors (TKIs) such as afatinib. Importantly,... |